Prevalence of Drug Resistance Mutations and Non-B Subtypes in Newly Diagnosed HIV-1 Patients in Denmark

References

• Conlon CP, Klenerman P, Edwards A, Larder BA, Phillips RE. Heterosexual transmission of human immunodeficiency virus type 1 variants associated with zidovudine resistance. J Infect Dis 1994; 169: 411–5.
   Google Scholar
• Angarano G, Monno L, Appice A, Giannelli A, Romanelli C, Fico C, Pastore G. Transmission of zidovudine-resistant HIV-1 through heterosexual contact. AIDS 1994; 8: 1013–4.
   Google Scholar
• Erice A, Mayers DL, Strike DG, Sannerud KJ, Mc Cutchan FE, Henry K, Balfour HH Jr. Brief report: primary infection with zidovudine-resistant human immunodeficiency virus type 1. N Engl J Med 1993; 328: 1163–5.
   Google Scholar
• Veenstra J, Schuurman, Cornelissen M, van’t Wout AB, Boucher CAB, Schuitemaker H, et al. Transmission of zidovudine–resistant human immunodeficiency virus type 1 variants following deliberate injection of blood from a patient with AIDS: characteristics and natural history of the virus. Clin Infect Dis 1995; 21: 556–60.
   PubMedGoogle Scholar
• Wegner SA, Brodine SK, Mascola JR, Tasker SA, Shaffer RA, Starkey MJ, et al. Prevalence of genotypic and phenotypic resistance to anti-retroviral drugs in a cohort of therapy-naϊve HIV-1 infected US military personnel. AIDS 2000; 14: 1009–15.
   PubMed Web of Science ®Google Scholar
• Alexander CS, Dong W, Chan K, Jahnke N, O’Shaughnessy MV, Mo T, et al. HIV protease and reverse transcriptase variation and therapy outcome in antiretroviral-naϊve individuals from a large North American cohort. AIDS 2001; 15: 601–7.
   Google Scholar
• Little SJ, Daar ES, D’Aquila RT, Keiser PH, Connick E, Whitcomb JM, et al. Reduced antiretroviral drug susceptibility among patients with primary HIV infection. JAMA 1999; 282: 1142–9.
   Google Scholar
• Boden D, Hurley A, Zhang L, Cao Y, Guo Y, Jones E, et al. HIV-1 drug resistance in newly infected individuals. JAMA 1999; 282(12): 1135–41.
   PubMed Web of Science ®Google Scholar
• Yerly S, Kaiser L, Race E, Bru J-P, Clavel F, Perrin L. Transmission of antiretroviral drug-resistant HIV-1 variants. Lancet 1999; 354: 729–33.
   Google Scholar
• Balotta C, Berlusconi A, Pan A, Violin M, Riva C, Colombo MC, et al. Prevalence of transmitted nucleoside analogueresistant HIV-1 strains and pre-existing mutations in pol reverse transcriptase and protease region: outcome after treatment in recently infected individuals. Antivir Ther 2000; 5: 7–14.
   PubMed Web of Science ®Google Scholar
• Brenner B, Wainburg MA, Salomon H, Rouleau D, Dascal A, Spira B, et al. Resistance to antiretroviral drugs in patients with primary HIV-1 infection. Int J Antimicrob Agents 2000; 16: 429–34.
   PubMed Web of Science ®Google Scholar
• Birk M, Sönnerborg YA. Variations in HIV-1 pol gene associated with reduced sensitivity to antiretroviral drugs in treatment-naϊve patients. AIDS 1998; 12: 2369–75.
   PubMedGoogle Scholar
• Toni TA, Masquelier B, Bonard D, Faure M, Caumont A, Dahourou G, et al. Genotypic diversity of HIV-1 in recently infected patients from Abidjan (Cote d’Ivoire) and relationship to drug resistance. Eighth Conference on Retroviruses and Opportunistic Infections, Chicago, USA, 4–8 February 2001, Abstr. 457.
   Google Scholar
• Carpenter CC, Cooper DA, Fischl MA, Gatell JM, Gazzard BG, Hammer SM, et al. Antiretroviral therapy in adults: updated recommendations of the International AIDS Society–USA panel. JAMA 2000; 283: 381–90.
   PubMed Web of Science ®Google Scholar
• The Euroguidelines Group for HIV Resistance. Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part treatment management: recommendations for the European setting. AIDS 2001; 15: 309–20.
   PubMed Web of Science ®Google Scholar
• Brodine SK, Shaffer RA, Starkey MJ, Tasker SA, Gilcrest JL, Louder MK, et al. Drug resistance patterns, genetic subtypes, clinical features, and risk factors in military personnel with HIV seroconversion. Ann Intern Med 1999; 131: 502–6.
   PubMed Web of Science ®Google Scholar
• Machuca R, Bogh M, Salminen M, Gerstoft J, Kvinesdal B, Pedersen C, et al. HIV-1 subtypes in Denmark. Scand J Infect Dis 2001; 33: 697–701.
   PubMedGoogle Scholar
• Felsenstein J. 1993. PHYLIP (phylogeny interference package) version 3.5c. Department of Genetics, University of Washington, Seattle, USA.
   Google Scholar
• Kemp SD, Bloor S and the FASP group resistance study group. Two distinct mutational pathways in HIV-1 RT confer zidovudine lamivudine dual resistance. International workshop on HIV drug resistance. AIDS 1998; 12: abstract 11.
   PubMedGoogle Scholar
• Brown AJL, Precious HM, Whitcomb JM, Wong JK, Quigg M, Huang W, et al. Reduced susceptibility of human immunodeficiency virus type 1 (HIV-1) from patients with primary HIV infection to non-nucleoside reverse transcriptase inhibitors is associated with variation at novel amino acid sites. J Virol 2000; 74: 10269–73.
   PubMed Web of Science ®Google Scholar
• National surveillance of communicable diseases. HIV-report 2nd half-year 2000, 2001; 10.
   Google Scholar
• Duwe S, Brunn M, Altmann D, Hamouda O, Schmidt B, Walter H, et al. Frequency of genotypic and phenotypic drug-resistant HIV-1 among therapy-naϊve patients of the German seroconverter study. J Acquir Immune Defic Syndr 2001; 26: 266–73.
   PubMed Web of Science ®Google Scholar
• Salomon H, Wainburg MA, Brenner B, Quan Y, Rouleau D, Coté P, et al. Prevalence of HIV-1 resistance to antiretroviral drugs in 81 individuals newly infected by sexual contact or injecting drug use. AIDS 1999; 14: F17–23.
   Google Scholar
• Simon V, Vanderhoeven J, Hurley A, Ramratnam B, Louie M, Dawson K, et al. Evolving patterns of HIV-1 resistance to antiretroviral agents in newly infected individuals. AIDS 2002; 16: 1511–9.
   PubMed Web of Science ®Google Scholar
• Little SJ, Holte S, Routy JP, Daar ES, Markowitz M, Collier AC, et al. Antiretroviral drug resistance among patients recently infected with HIV. N Engl J Med 2002; 347: 385–94.
   PubMed Web of Science ®Google Scholar
• Puig T, Perrez-Olmeda M, Rubio A, Ruiz L, Briones C, Franco JM, et al. Prevalence of genotypic resistance to nucleoside analogues and protease inhibitors in Spain. AIDS 2000; 14: 727–32.
   PubMed Web of Science ®Google Scholar
• Van Varenbergh K, Debaisieux L, De Cabooter N, DeClercq C, Desmet K, Fransen K, et al. Prevalence of genotypic resistance among antiretroviral drug-naϊve HIV-1-infected patients in Belgium. Antivir Ther 2001; 6: 63–70.
   PubMedGoogle Scholar
• De Ronde A, Van Dooren M, Van der Hoek L, Bouwhuis D, De RooijE, Van Gemen B, et al. Establishment of new transmissible and drug-sensitive human immunodeficiency virus type 1 wild types due to transmission of nucleoside analogue-resistant virus. J Virol 2001; 75: 595–602.
   PubMed Web of Science ®Google Scholar
• Goudsmit J, De Ronde A, De RooijE, De Boer R. Broad spectrum of in vivo fitness of human immunodeficiency virus type 1 subpopulations differing at reverse transcriptase codons 41 and 215. J Virol 1997; 71: 4479–84.
   PubMed Web of Science ®Google Scholar
• Gerardo Garcia-Lerma J, Nidtha S, Blumhoff K, Weinstock H, Heneine W. Increased ability for selection of zidovudine resistance in a distinct class of wild-type HIV-1 from drug-naϊve persons. Proc Natl Acad Sci USA 2000; 98: 13907–12.
   Google Scholar
• Goudsmit J, Weverling GJ, van der Hoek, de Ronde A, Miedema, Coutino RA, et al. Carrier rate of zidovudineresistant HIV-1: the impact of failing therapy on tranmission of resistant strains. AIDS 2001; 15: 2293–301.
   Google Scholar
• Bacheler LT, Ploughman L, Hertogs K, Larder B. Impact of baseline NNRTI resistance on the efficacy of Efavirenz combination therapy in NNRTI therapy naϊve patients (Study DMP 266–006) 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, 17 /20 September 2000. Abstract 1278.
   Google Scholar
• Pillay D, Taylor S, Richman D. Incidence and impact of resistance against approved antiretroviral drugs. Rev Med Virol 2000; 10: 231–53.
   Google Scholar
• Alexander CS, Dong W, Schechter MT, O’Shaughnessy MV, Strathdee SA, Mo T, et al. Prevalence of primary HIV drug resistance among seroconverters during an explosive outbreak of HIV infection among injecting drug users. AIDS 1999; 13: 981–5.
   Google Scholar
• Yahi N, Fantini J, Tourres C, Tivoli N, Koch N, Tamalet C. Use of drug resistance sequence data for the systematic detection of non-B human immunodeficiency virus type 1 (HIV-1) subtypes: how to create a sentinel site for monitoring the genetic diversity of HIV-1 at a country scale. J Infect Dis 2001; 183: 1311–7.
   PubMedGoogle Scholar
• Hirsch MS, Brun-Vezinet F, D’Aquila RT, Hammer SM, Johnson V, Kuritzkes DR, et al. Antiretroviral drug resistance testing in adult HIV-1 infection. JAMA 2000; 18: 2417–26.
   Web of Science ®Google Scholar